Pfenex announced this week that it submitted to the FDA a New Drug Application (NDA) for its PF708, a teriparatide follow-on referencing Eli Lilly’s Forteo for the treatment of osteoporosis.
Pfenex announced this week that it submitted to the FDA a New Drug Application (NDA) for its PF708, a teriparatide follow-on referencing Eli Lilly’s Forteo for the treatment of osteoporosis.
“We are pleased to submit to the FDA an NDA for PF708 as a proposed therapeutic equivalent to Forteo, which achieved $1.7 billion in global sales in 2017,” Eef Schimmelpennink, CEO of Pfenex, said in a statement announcing the submission. Schimmelpennink added that the timing of the submission could allow for a commercial launch of the follow-on as early as the fourth quarter of 2019, should the FDA approve the product.
The data package for PF708 includes data from a 24-week study in 181 patients with osteoporosis, results of which were announced earlier this year. The primary end point of the study was incidence of antidrug antibodies (ADAs) at week 24, and secondary end points included the mean percentage changes in lumbar-spine bone mineral density (BMD) and median percentage changes in bone turnover markers after week 24, as well as pharmacokinetic parameters for up to 4 hours after the first dose.
In total, 2 patients in the PF708 arm and 2 patients in the reference arm developed ADAs during the study period. The follow-on and reference teriparatide demonstrated comparable effects, with no statistically significant differences observed, on lumbar spine BMD and on both N-terminal propeptide of type 1 procollagen (a marker of bone formation) and cross-linked C-terminal telopeptide of type 1 collagen (a marker of bone reabsorption). There were no significant differences in the proportion of patients who experienced adverse events (AEs), or in the severity of AEs, between the 2 study arms.
While teriparatide follow-on products are regulated as biosimilars in the European Union (and biosimilars including Gedeon Richter’s Terrosa and Stada’s Movymia have already been approved for marketing), in the United States, such products are regulated as drugs. As such, Pfenex has submitted an 505(b)(2) NDA rather than an abbreviated Biologics License Application for the product.
A key feature of 505(b)(2) NDAs is that the pathway allows manufacturers to submit their drug products for FDA review by including data collected by the reference product sponsor, though, like the biosimilar approval pathway, the follow-on must be shown to be similar to the reference through bioanalytical testing, preclinical studies, and (in some cases) clinical trials. According to Pharmacy Times®, a sister publication of The Center for Biosimilars®, another key feature of the pathway is that drugs approved via 505(b)(2) NDAs are eligible for 3 to 5 years of market exclusivity (versus a potential 6 months of market exclusivity for drugs approved as first generics).
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.